Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 490.60K | 556.70K | 467.20K | 364.70K | 376.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 490.60K | 556.70K | 467.20K | 364.70K | 376.70K |
| Cost of Revenue | 216.10K | 278.10K | 240.10K | 168.20K | 137.20K |
| Gross Profit | 274.40K | 278.60K | 227.10K | 196.50K | 239.50K |
| SG&A Expenses | 557.40K | 552.30K | 1.09M | 868.50K | 810.00K |
| Depreciation & Amortization | 98.60K | 95.20K | 41.70K | 35.00K | 36.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 886.30K | 915.20K | 1.41M | 1.10M | 1.00M |
| Operating Income | -395.70K | -358.50K | -938.70K | -739.10K | -626.20K |
| Income Before Tax | -601.80K | -514.70K | -1.18M | -991.90K | -803.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -601.80K | -514.70K | -1.18M | -991.90K | -803.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -601.80K | -514.70K | -1.18M | -991.90K | -803.00K |
| EBIT | -395.70K | -358.50K | -938.70K | -739.10K | -626.20K |
| EBITDA | -365.90K | -328.00K | -913.60K | -704.10K | -589.50K |
| EPS Basic | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 82.55M | 131.38M | 125.76M | 124.17M | 123.12M |
| Average Diluted Shares Outstanding | 82.55M | 131.38M | 125.76M | 124.17M | 123.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |